Fresenius Kabi to Establish R&D Center for Biosimilars in Switzerland

Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology


  • Fresenius Kabi has invested $15M in the R&D center located at Eysins, Switzerland having 100 employees from 20 nationalities plus with the office of its Biosimilar Business Unit and plans to expand the team adding experts from different areas of specialization within biosimilars and their development in future   
  • The focus of the center is to strengthen Fresenius Kabi’s capability to enable access for modern biosimilar treatment options for patients worldwide and will intensify biosimilars research and development in the areas of autoimmune diseases and oncology
  • In 2019, the company launched its first biosimilar. The company has a product portfolio of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products and has 37,000 employees WW, resulted $6.5B of WW sales in 2018  

Click here to­ read full press release/ article | Ref: Fresenius Kabi | Image: Twitter